March 05, 2018
Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial
In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Read the full article in The American of Tropical Medicine and Hygiene.
More from CNAS
-
Sharper: Day One
Commentary
The Biden-Harris administration will confront a range of national security challenges from the moment it takes office....
By Chris Estep
-
How the Defense Budget Could Actually Increase (Slightly)
Commentary
Once all is said and done, it is more likely that defense spending will end up growing rather than shrinking....
By Diem Salmon
-
The President (Probably) Isn’t Going To Nuke Anything This Week
Commentary
The idea that presidents are able to use nuclear weapons in any way they personally desire is not correct....
By Tom Shugart
-
Defense Priorities Under Biden
Video
Richard Fontaine and Robert O. Work join the World Affairs Council of Greater Houston to discuss the Biden Pentagon and the future of U.S. defense. Watch the full conversatio...
By Richard Fontaine & Robert O. Work
